|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||72.77 - 74.24|
|52 Week Range||60.14 - 84.00|
|PE Ratio (TTM)||11.30|
|Forward Dividend & Yield||2.00 (2.93%)|
|1y Target Est||N/A|
A solid 2019 PBM selling season is a significant positive for CVS Health's (CVS) growth. The company completes more than 70% of its client renewals, almost in line with the prior-year level.
Billionaire entrepreneur and investor Mark Cuban appeared on CNBC recently and sounded a cautious tone about the stock market. In this column, I will explain why someone who is cautious about the stock market can be bullish about NFLX stock and AMZN stock. Cuban does own four dividend stocks.
HSN, once known as the Home Shopping Network, is getting an image makeover. A U.S. television network where shoppers can buy everything from electronics to kitchen gadgets, HSN is overhauling its lineup to offer more beauty products while adding streamed video content to win over shoppers without cable TV. A division of Qurate Retail Group, the network is facing growing competition from Amazon Inc. and Evine Live Inc for consumers like 24-year old Erin Bounds, who regard buying products through TV shows a relic of the past.
Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs. Express Scripts is in talks with biotechnology companies Biomarin Pharmaceutical Inc (BMRN.O), Spark Therapeutics Inc (ONCE.O) and Bluebird Bio Inc (BLUE.O) to have its specialty pharmaceutical business exclusively distribute their new haemophilia therapies when they are expected to become available in 2019 and 2020, Chief Medical Officer Steve Miller told Reuters in an interview.
CVS Health (CVS) released its second-quarter results on August 8 before the market opened. The company’s revenues for the quarter grew 2.2% YoY (year-over-year) to $46.7 billion and beat the estimate by 0.8%. CVS Health’s earnings increased 27.1% YoY to $1.6 per share and exceeded the forecast of $1.6 per share.
So far, 91% of the companies in the S&P 500 have reported their third-quarter earnings. Last week was mediocre for the market. The S&P 500 Index (SPY) fell 0.25% for the week ending August 10. Last week was average for most of the sectors in the index.
The rating was placed on review for possible downgrade due to the Rite Aid Corporation ("Rite-Aid") senior unsecured rating being placed on review for possible downgrade by Moody's on August 9, 2018. Rite-Aid was placed on review for possible downgrade due to Rite-Aid's announcement that it has terminated its merger agreement with Albertsons Companies, Inc. The merger termination leaves Rite-Aid in a weaker position as it lacks the scale or the balance sheet to compete in the changing pharmacy landscape with much larger and well capitalized competitors like CVS Health and Walgreens Boots Alliance, Inc. The ratings of Credit Tenant Lease (CTL) deals are primarily based on the senior unsecured debt rating (or the corporate family rating) of the tenants leasing the real estate collateral supporting the bonds.
Pharmacy-benefit managers may drive hard bargains with drug manufacturers, but they keep finding ways to boost their bottom line at the expense of employers and patients.
CVS Health’s (CVS) better-than-expected second-quarter results managed to please investors. The company’s share price soared 6% during the day on August 8 before finally settling at $68.17, 4.2% higher than the previous day’s close.
As discussed in the previous section, six analysts have downgraded Walgreens Boots Alliance (WBA) since Amazon’s (AMZN) acquisition of PillPack in late June. As a result, Walgreens’s overall ratings have come down drastically. The company, which was rated 2.3 before the acquisition on June 28, is now ranked as a 2.7. Ratings are on a scale where one is a “strong buy,” and five is a “strong sell.”
Moody's Investors Service ("Moody's") today placed the ratings of Rite Aid Corporation (Rite-Aid) on review for downgrade including its Corporate Family Rating of B2 and its Probability of Default Rating of B2-PD. The review for downgrade is prompted by Rite-Aid's announcement that it has terminated its merger agreement with Albertsons Companies, Inc.
CVS Health (CVS) once again cruised ahead of bottom line expectations when it reported its second-quarter results yesterday morning. Its adjusted EPS rose 27.1% YoY (year-over-year) to $1.69, $0.08 more than the Thomson Reuters I/B/E/S estimate. This was the tenth consecutive earnings beat for the company.
Rite Aid had a horrid week. The stock has been pummeled by a spate of bad news, raising questions about how Rite Aid will continue to stack up against its competitors on pricing, footprint and innovation edge. The slide thus far was punctuated by a collapse of a merger agreement with Albertsons Cos. grocery chain, sinking the shares over 9% on Thursday to $1.58 per share.
CVS Health (CVS) posted better-than-expected quarterly sales when it reported its second-quarter results on August 8. Its top line improved 2.2% YoY (year-over-year) to $46.7 billion.
Some Rite Aid stockholders were apparently unwilling to approve the pharmacy chain's merger with grocer Albertsons in a vote scheduled Thursday, so on Wednesday night, Rite Aid and Albertsons called off the merger. Rite Aid's balky shareholders may rue their opposition to the deal. In heavy trading, Rite Aid (RAD) stock was down about 10% early Thursday afternoon, to just $1.56 a share. Pharmacies are in the thick of the transformation of the health care economy. CVS Health (CVS) wants to merge with insurer Aetna (AET), while benefits manager Express Scripts Holdings (ESRX) aims to join insurer Cigna (CI).
Rite Aid notes that the reason it is no longer moving forward with the merger is due to the views of its shareholders. Rite Aid also points out that the agreement between it and Albertsons doesn’t require a payment from either company for the cancellation of the merger agreement. “We will continue building momentum for key areas of our business like our innovative Wellness store format, highly successful customer loyalty program and expanded pharmacy service offerings, as we also enhance our omni-channel and own brand offerings to strengthen our competitive position and create long-term value for stockholders,” Rite Aid Chairman and CEO John Standley said in a statement.
CVS Health (CVS) reported its second-quarter earnings results on August 8. The pharmacy giant reported better-than-expected top and bottom line results during the quarter.
Walgreens Boots Alliance (WBA) stock has been in the red almost throughout the whole year so far. Interestingly, the pharmacy giant’s stock performance hasn’t been driven by its own financial performance, but by Amazon’s expansion plans in the pharma space. Walgreens has reported quarterly results for the first three fiscal quarters of 2018 this year.
Zacks.com highlights: CVS Health, Meritage Homes, Big Lots, Rayonier Advanced Materials, ON Semiconductor and PCM
CVS Health Corp. Chief Executive Larry Merlo said Wednesday that industry middlemen aren’t responsible for increasing U.S. drug prices, noting that prices are rising faster for medicines with smaller manufacturer rebates. CVS owns Caremark, one of the biggest pharmacy-benefit managers, which process prescriptions for insurers or companies that pay for medicines and use their size to negotiate with drugmakers and pharmacies. Mr. Merlo said CVS expects 3%, or about $300 million, of its 2018 earnings to come from rebates it pockets.